High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results

Brachytherapy

Volumn 11, Issue 2, 2012, Pages 105-110

  Prada, Pedro J ^a   Jimenez, Isabel ^a   González Suárez, Herminio ^a   Fernández, José ^a   Cuervo Arango, Covadonga ^a   Mendez, Lucia ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Brachytherapy; High dose rate; Monotherapy; Prostate cancer

Indexed keywords

HYALURONIC ACID;

ADULT; AGED; ANUS DISEASE; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSIMETRY; DYSURIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE;

ADJUVANTS, IMMUNOLOGIC; BRACHYTHERAPY; CHEMORADIOTHERAPY; GASTROINTESTINAL DISEASES; HUMANS; HYALURONIC ACID; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84857798075     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.05.003     Document Type: Article

References (18)

1. Mettlin C.J., Murphy G.P., McDonald C.J., et al. The National Cancer Data Base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer 1999, 86:1877-1882.
2. Lee W.R., Moughan J., Owen J., et al. The 1999 patterns of care study of radiotherapy in localized prostatic carcinoma: A comprehensive survey of prostate brachytherapy in the United States. Cancer 2003, 98:1987-1994.
3. Ash D., Flynn A., Battermann J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000, 57:315-321.
4. Battermann J.J., Boon T.A., Moerland A., et al. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004, 71:23-28.
5. Fleming I., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual 1997, Lippincitt-Raven, Philadelphia, PA. 5th ed.
6. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
7. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
8. Duchesne G.M., Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 44:747-748. [editorial].
9. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:265-276.
10. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.
11. Prada P.J., Fernández J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
12. Prada P.J., González H., Menéndez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
13. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
14. Martinez A.A., Pataki I., Edmunson G., et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001, 49:61-69.
15. Ghadjar P., Keller T., Rentsch C.A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
16. Martin T., Baltas D., Kurek R., et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004, 180:225-232.
17. Yoshioka Y., Takayuki N., Yoshida K., et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000, 48:675-681.
18. Konishi K., Yoshioka Y., Isohashi F., et al. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:1003-1007.